SGMT ▲ +0.7% - Sagimet Biosciences Inc.
$SGMT - Sagimet Announces Positive Full 52-Week Results from License Partner Ascletis' Phase 3 Open-Label Extension Clinical Trial of Denifanstat in Acne Presented at EADV 2026
30-SEP-2026 06:00 AM ET
Share this post
More filings for $SGMT
SGMT ▲ +14.1% - Sagimet Biosciences Inc.Sep 30, 2026SGMT ▼ -1.0% - Sagimet Biosciences Inc.Sep 28, 2026SGMT ▲ +1.1% - Sagimet Biosciences Inc.Sep 2, 2026SGMT - Sagimet Biosciences Inc. - SEC Filing Update (14-AUG-2026) | ThinkSabio - Stocks SimplifiedAug 14, 2026$SGMT SEC Filing Update (30-JUL-2026) | ThinkSabio - Stocks SimplifiedJul 30, 2026
View full $SGMT filing history →💬 Comments
Loading comments…
Leave a comment